



Attorney Docket No.: 21327-701-01

SEQUENCE LISTING

<110> Gill, Parkesh
Masood, Rizwan

<120> METHOD AND COMPOSITION FOR TREATMENT OF
KAPOSI'S SARCOMA

<130> 21327-701-01

<140> US 09/487,023
<141> 2000-01-19

<150> US 60/037,004
<151> 1997-01-31

<150> US 09/016,541
<151> 1998-01-30

<160> 33

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense oligonucleotide to a naturally occurring
sequence

<400> 1
agacagcaga aagttcatgg t

21

<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense oligonucleotide to a naturally occurring
sequence

<400> 2
tggcttgaag atgtactcga t

21

<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 3
attgcagcag ccccccacatc g

21

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 4
gcagccccca catcgatca g

21

<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 5
cccacatcggt atcaggggca c

21

<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 6
tcggatcagg ggcacacagg a

21

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 7
caggggcaca caggatggct t

21

BEST AVAILABLE COPY

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 8
cacacaggat ggcttgaaga t

21

<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 9
acacaggatg gcttgaagat g

21

<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 10
cacaggatgg cttgaagatg t

21

<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 11
acaggatggc ttgaagatgt a

21

<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence

<220>

BEST AVAILABLE COPY

<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 12
caggatggct tggagatgtac

21

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 13
aggatggctt ggagatgtac t

21

<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 14
ggatggctt aagatgtact c

21

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 15
gatggcttga agatgtactc g

21

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 16
atggcttcaa gatgtactcg a

21

BEST AVAILABLE COPY

<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 17
ggcttgaaga tgtactcgat c

21

<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 18
gcttgaaagat gtactcgatc t

21

<210> 19
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 19
cttgaagatg tactcgatct c

21

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 20
ggatggcttg aagatgtact

20

<210> 21
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

BEST AVAILABLE COPY

<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 21
ggatggcttg aagatgtac .

19

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 22
ggatggcttg aagatgtac

18

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 23
ggcttgaaga tgtactcgat

20

<210> 24
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 24
gcttgaagat gtactcgat

19

<210> 25
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 25
cttgaagatg tactcgat

18

BEST AVAILABLE COPY

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 26
tggcttgaag atgtactcga

20

<210> 27
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 27
tggcttgaag atgtactcg

19

<210> 28
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 28
gggcacacag gatggcttga agatgtactc gat

33

<210> 29
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> VEGF antisense oligonucleotide in Kaposi's
sarcoma, ovarian carcinoma, and melanoma

<400> 29
gggcacacag gatggcttga aga

23

<210> 30
<211> 62
<212> DNA
<213> Homo sapiens

<220>

BEST AVAILABLE COPY

<221> CDS
 <222> (2)...(61)
 <223> VEGF-A

<400> 30
 a gat cga gta cat ctt caa gcc atc ctg tgt gcc cct gat gcg atg cgg 49
 Asp Arg Val His Leu Gln Ala Ile Leu Cys Ala Pro Asp Ala Met Arg
 1 5 10 15

ggg ctg ctg caa t 62
 Gly Leu Leu Gln
 20

<210> 31
 <211> 62
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(60)
 <223> VEGF-C

<400> 31
 cga caa aca cct tct tta aac ctc cat gtg tgt ccg tct aca gat gtg 48
 Arg Gln Thr Pro Ser Leu Asn Leu His Val Cys Pro Ser Thr Asp Val
 1 5 10 15

ggg gtt gct gca at 62
 Gly Val Ala Ala
 20

<210> 32
 <211> 62
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (2)...(61)
 <223> VEGF-D

<400> 32
 g tac caa cac att ctt caa gcc ccc ttg tgt gaa cgt gtt ccg atg tgg 49
 Tyr Gln His Ile Leu Gln Ala Pro Leu Cys Glu Arg Val Pro Met Trp
 1 5 10 15

tgg ctg ttg caa t 62
 Trp Leu Leu Gln
 20

BEST AVAILABLE COPY

<210> 33

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Scrambled VEGF antisense oligonucleotide in
Kaposi's sarcoma, ovarian carcinoma, and melanoma

<400> 33

tacgttagtat ggtgtacgat c

21

BEST AVAILABLE COPY